Syndecan-4 has been targeted or utilized as part of therapeutic approaches in nonmalignant diseases, and this knowledge could be utilized in a cancer context in the future: For example, antibody-mediated inhibition of syndecan-4 has been proposed as a treatment for osteoarthritis [145,146]. Here, SDC4 is linked to cancer.